Four Leiden University researchers have each received €2.5 million ERC Advanced Grants to pursue innovative projects in social inequality, medical placebo effects, type 1 diabetes treatment, and community-based climate adaptation, aiming to make significant scientific and societal contributions.
At BIO International Convention in Boston, biotech ambition turns into partnership and progress. This year, Leiden Bio Science Park joined the Dutch delegation at the Netherlands Pavilion, right alongside innovators, investors, and policymakers all working to shape the future of…
Professor Bart Roep of LUMC has received a €2.5 million ERC Advanced Grant to develop a potential cure for type 1 diabetes by creating immune-resistant insulin-producing cells. His research focuses on reducing beta cell stress and using targeted drug delivery…
We recently hosted Tjerk Opmeer from the Ministry of Economic Affairs at Leiden Bio Science Park to share insights into building a shared investment agenda for Dutch biotech. Joined by leaders from universities, industry, and government, Esther Peters from Leiden…
A new collaboration between TNO, Proefdiervrij, and pharmaceutical company Galapagos, called MechPath, is accelerating the transition to animal-free drug development. By combining patient data, lab-based human cell models, and artificial intelligence, the MECHanistic PATHology (MechPath) approach allows researchers to identify…
The first Works Council Community meeting at Leiden Bio Science Park tackled workplace conduct and culture through honest, practical dialogue. With HR and legal experts in the room, the session marked the start of a collaborative effort to foster safer,…
EMA visited Leiden Bio Science Park to explore how regulatory tools can better support early-stage innovation. The visit connected EMA representatives with local leaders across academia, investment, and biotech development for a forward-looking exchange on speeding therapies to patients.
A joint effort between Leiden University’s Professor Ubbink’s lab and ZoBio’s Assay Development and Screening team has advanced fragment-based drug discovery targeting membrane proteins. Supported by a Dutch Research Council (NWO) AES grant, the project utilized protein-lipid nanodiscs to study…
Leyden Labs has secured €20 million in financing from the European Investment Bank (EIB), supported by HERA Invest under the EU’s InvestEU programme. The funding will support the clinical development of Leyden Labs’ PanFlu nasal spray, an intranasal antibody therapy…
Researchers at Leiden University Medical Center (LUMC), in collaboration with Erasmus MC and the Oncode Institute, have developed a novel vaccine targeting non-small cell lung cancer (NSCLC). This vaccine aims to expose cancer cells that have evaded the immune system,…
The May TechTalk at Leiden Bio Science Park focused on women’s health as a key driver of innovation, featuring expert insights on cardiology, diagnostics, early development, and maternal care. The event sparked lasting conversations and a shared call for more…
Leiden University Medical Center (LUMC) has achieved a national milestone by treating the first Dutch patient with an autoimmune disease using CAR-T cell therapy. This approach, previously reserved for cancer treatment, was applied to a patient with severe neurological lupus…